In addition, the findings indicate that an LN-specific treatment with 17β-estradiol, ERα agonists, and ERα's downstream signals (24) may be considered a therapeutic approach for treating middle-aged patients with MS and patients with progressive MS that has nonremitting IFN-β-resistant, or severe gray matter atrophy phenotypes. Here, ESR1 is linked to myeloid sarcoma.